Literature DB >> 34573382

Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer.

Eleni Anastasiadou1, Elena Messina1, Tiziana Sanavia2, Vittorio Labruna1, Simona Ceccarelli1, Francesca Megiorni1, Giulia Gerini1, Paola Pontecorvi1, Simona Camero3, Giorgia Perniola4, Mary Anna Venneri1, Pankaj Trivedi1, Andrea Lenzi1, Cinzia Marchese1.   

Abstract

Epithelial ovarian cancer (EOC) outpaces all the other forms of the female reproductive system malignancies. MicroRNAs have emerged as promising predictive biomarkers to therapeutic treatments as their expression might characterize the tumor stage or grade. In EOC, miR-200c is considered a master regulator of oncogenes or tumor suppressors. To investigate novel miR-200c-3p target genes involved in EOC tumorigenesis, we evaluated the association between this miRNA and the mRNA expression of several potential target genes by RNA-seq data of both 46 EOC cell lines from Cancer Cell line Encyclopedia (CCLE) and 456 EOC patient bio-specimens from The Cancer Genome Atlas (TCGA). Both analyses showed a significant anticorrelation between miR-200c-3p and the protein phosphatase 3 catalytic subunit γ of calcineurin (PPP3CC) levels involved in the apoptosis pathway. Quantitative mRNA expression analysis in patient biopsies confirmed the inverse correlation between miR-200c-3p and PPP3CC levels. In vitro regulation of PPP3CC expression through miR-200c-3p and RNA interference technology led to a concomitant modulation of BCL2- and p-AKT-related pathways, suggesting the tumor suppressive role of PPP3CC in EOC. Our results suggest that inhibition of high expression of miR-200c-3p in EOC might lead to overexpression of the tumor suppressor PPP3CC and subsequent induction of apoptosis in EOC patients.

Entities:  

Keywords:  PPP3CC; TCGA and CCLE databases; apoptosis; calcineurin; epithelial ovarian cancer; miRNA

Mesh:

Substances:

Year:  2021        PMID: 34573382      PMCID: PMC8470066          DOI: 10.3390/genes12091400

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  53 in total

Review 1.  Metazoan MicroRNAs.

Authors:  David P Bartel
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

2.  Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.

Authors:  Lisa Héron-Milhavet; Celine Franckhauser; Vanessa Rana; Cyril Berthenet; Daniel Fisher; Brian A Hemmings; Anne Fernandez; Ned J C Lamb
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

3.  AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.

Authors:  Maud Privat; Corinne Aubel; Stephanie Arnould; Yves Communal; Marc Ferrara; Yves-Jean Bignon
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

4.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

5.  Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.

Authors:  Qiong Jin; Beihua Kong; Xingsheng Yang; Baoxia Cui; Yongqing Wei; Qifeng Yang
Journal:  In Vivo       Date:  2007 Jul-Aug       Impact factor: 2.155

6.  Caspase-3-mediated cleavage of Akt: involvement of non-consensus sites and influence of phosphorylation.

Authors:  Arezu Jahani-Asl; Ajoy Basak; Benjamin K Tsang
Journal:  FEBS Lett       Date:  2007-05-24       Impact factor: 4.124

7.  Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.

Authors:  Bing Xin; Kai-Qiang Ji; Yi-Si Liu; Xiao-Dong Zhao
Journal:  J Ovarian Res       Date:  2019-08-09       Impact factor: 4.234

8.  Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation.

Authors:  Nicole S Anderson; Leslie Turner; Sandra Livingston; Ren Chen; Santo V Nicosia; Patricia A Kruk
Journal:  J Ovarian Res       Date:  2009-10-25       Impact factor: 4.234

9.  Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.

Authors:  Yong-Wan Kim; Eun Young Kim; Doin Jeon; Juinn-Lin Liu; Helena Suhyun Kim; Jin Woo Choi; Woong Shick Ahn
Journal:  Drug Des Devel Ther       Date:  2014-02-24       Impact factor: 4.162

Review 10.  miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition.

Authors:  Siti A Sulaiman; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2016-08-23       Impact factor: 5.810

View more
  1 in total

1.  Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression.

Authors:  Toshihiko Takeiwa; Yuichi Mitobe; Kazuhiro Ikeda; Kosei Hasegawa; Kuniko Horie; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.